Investigation of deaths because of COVID-19 under 55 years of age in a province

Öz

Aim: In this study, we aimed to evaluate people who died under the age of 55 due to COVID-19 according to age, gender and vaccination status. Methods: The information of people who passed away under the age of 55 were compiled from the applications of the Ministry of Health, Public Health Management System (HSYS), Vaccine Tracking System (ATS) and E-NABIZ. Calculations were made using the SPSS-21 program. Chi-square test and frequencies were calculated. Results: In the study, deaths were mostly between the ages of 40-49 and 50-55 (76%), 87.8% of deaths were seen in unvaccinated people, deaths were more common in patients with chronic diseases (75.9%), and in vaccinated patients with chronic diseases. It was found that deaths were less common between the vaccinated and unvaccinated. Conclusion: It has been scientifically proven that vaccination is extremely important and protective. For this reason, vaccination rates need to be increased rapidly in order to reduce deaths due to COVID-19. This is especially important in elderly individuals with chronic diseases.

Anahtar Kelimeler

• Covid-19
• Mortality
• Adulthood
• Epidemiogly

Bir ilimizdeki 55 Yaş Altı COVID-19’a bağlı ölümlerinin incelenmesi

Öz

Amaç: Bu çalışmamızda 55 yaş altında COVID-19 sebebiyle ölen kişileri yaş, cinsiyet, aşılanma durumuna göre değerlendirmeyi amaçladık. Yöntem: Sağlık Bakanlığı’nın uygulamaları olan Halk Sağlığı Yönetim Sistemi (HSYS), Aşı Takip Sistemi (ATS) ve E-NABIZ uygulamalarından 55 yaş altı vefat eden kişilerin bilgileri derlenmiştir. SPSS-21 programı kullanılarak hesaplamalar yapılmıştır. Ki kare testi ve frekanslar hesaplanmıştır. Bulgular: Çalışmada ölümlerin en çok 40-49 ve 50-55 yaş aralığında olduğu (%76), ölümlerin %87,8’ini aşı olmayanlarda görüldüğü, ölümlerin kronik hastalığı olanlarda daha fazla görüldüğü (%75,9), kronik hastalığı olan aşılılarda ölümlerin daha az görüldüğü bulunmuştur. Sonuç: Aşılanmanın son derece önemli ve koruyucu olduğu bilimsel olarak kanıtlanmıştır. Bu sebeple COVID-19’a bağlı ölümlerin azaltılması için aşılanma oranlarının hızla artırılması gerekmektedir. Özellikle kronik hastalığı olan ileri yaştaki bireylerde bu çok daha önemlidir.

Anahtar Kelimeler

• Covid-19
• Mortalite
• Erişkin
• Epidemiyoloji

Kaynakça

1. Ciotti M, Ciccozzi M, Terrinoni A, Jiang W-C, Wang C-B, Bernardini S. The COVID-19 pandemic. Critical Reviews in Clinical Laboratory Sciences. 2020;57(6):365-88.
2. Buran D, Dikmen AU. Ülkemizde ve Dünyada COVID-19 Epidemiyolojisi. Turkey Health Literacy Journal2021. p. 119-26.
3. Centers for Disease Control and Prevention. About variants of the virus that causes COVID-19. Accessed July2021. p. 2021.
4. Wang C, Liu B, Zhang S, Huang N, Zhao T, Lu Q-B, et al. Differences in incidence and fatality of COVID-19 by SARS-CoV-2 Omicron variant versus Delta variant in relation to vaccine coverage: A world-wide review. Journal of Medical Virology. 2023;95(1):e28118.
5. Rashedi J, Mahdavi Poor B, Asgharzadeh V, Pourostadi M, Samadi Kafil H, Vegari A, et al. Risk factors for COVID-19. Infez Med. 2020;28(4):469-74.
6. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-6.
7. Wolff D, Nee S, Hickey NS, Marschollek M. Risk factors for Covid-19 severity and fatality: a structured literature review. Infection. 2021;49(1):15-28.
8. Deng G, Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients with COVID-19. Critical Care. 2020;24(1):179.

9. Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. International Journal of Infectious Diseases. 2022;114:252-60.
10. Moline HL, Whitaker M, Deng L, Rhodes JC, Milucky J, Pham H, et al. Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years - COVID-NET, 13 States, February-April 2021. MMWR Morb Mortal Wkly Rep. 2021;70(32):1088-93.
11. Mayr FB, Talisa VB, Shaikh O, Yende S, Butt AA. Effectiveness of homologous or heterologous Covid-19 boosters in veterans. New England Journal of Medicine. 2022.
12. Nafilyan V, Bermingham CR, Ward IL, Morgan J, Zaccardi F, Khunti K, et al. Risk of death following COVID-19 vaccination or positive SARS-CoV-2 test in young people in England. Nature Communications. 2023;14(1):1541.
13. Flaxman S, Whittaker C, Semenova E, Rashid T, Parks RM, Blenkinsop A, et al. Assessment of COVID-19 as the Underlying Cause of Death Among Children and Young People Aged 0 to 19 Years in the US. JAMA Network Open. 2023;6(1):e2253590-e.
14. Bertran M, Amin-Chowdhury Z, Davies HG, Allen H, Clare T, Davison C, et al. COVID-19 deaths in children and young people in England, March 2020 to December 2021: An active prospective national surveillance study. PLOS Medicine. 2022;19(11):e1004118.
15. Kobo O, Abramov D, Fudim M, Sharma G, Bang V, Deshpande A, et al. Has the first year of the COVID-19 pandemic reversed the trends in CV mortality between 1999 and 2019 in the United States? European Heart Journal - Quality of Care and Clinical Outcomes. 2022:qcac080.
16. Mukherjee S, Pahan K. Is COVID-19 Gender-sensitive? Journal of Neuroimmune Pharmacology. 2021;16(1):38-47.
17. Tazerji SS, Shahabinejad F, Tokasi M, Rad MA, Khan MS, Safdar M, et al. Global data analysis and risk factors associated with morbidity and mortality of COVID-19. Gene Reports. 2022;26:101505.
18. Kang SJ, Jung SI. Age-Related Morbidity and Mortality among Patients with COVID-19. Infect Chemother. 2020;52(2):154-64.
19. Sasson I. Age and COVID-19 mortality. Demographic Research. 2021;44:379-96.
20. Khera N, Santesmasses D, Kerepesi C, Gladyshev VN. COVID-19 mortality rate in children is U-shaped. Aging (Albany NY). 2021;13(16):19954-62.
21. Israel A, Schäffer AA, Merzon E, Green I, Magen E, Golan-Cohen A, et al. Predicting COVID-19 severity using major risk factors and received vaccines. medRxiv. 2022.
22. Wang X, Du Z, Johnson KE, Pasco RF, Fox SJ, Lachmann M, et al. Effects of COVID-19 Vaccination Timing and Risk Prioritization on Mortality Rates, United States. Emerg Infect Dis. 2021;27(7):1976-9.
23. Altmann Daniel M, Boyton Rosemary J. COVID-19 vaccination: The road ahead. Science. 2022;375(6585):1127-32.
24. Yek C, Warner S, Wiltz JL, Sun J, Adjei S, Mancera A, et al. Risk Factors for Severe COVID-19 Outcomes Among Persons Aged≥ 18 Years Who Completed a Primary COVID-19 Vaccination Series—465 Health Care Facilities, United States, December 2020–October 2021. Morbidity and Mortality Weekly Report. 2022;71(1):19.
25. Johnson AG. COVID-19 incidence and death rates among unvaccinated and fully vaccinated adults with and without booster doses during periods of Delta and Omicron variant emergence—25 US Jurisdictions, April 4–December 25, 2021. MMWR Morb Mortal Wkly Rep. 2022;71.
26. Nordström P, Ballin M, Nordström A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. The Lancet. 2022;399(10327):814-23.
27. Saban M, Myers V, Wilf-Miron R. Changes in infectivity, severity and vaccine effectiveness against delta COVID-19 variant ten months into the vaccination program: The Israeli case. Preventive Medicine. 2022;154:106890.